Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 9/20 | 0.49 |
| ▸ | PPARG | P37231 | 8/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | ECE1 | P42892 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607848 | 1.00 | APP (0.49) | APPPPARAPPARGCTSSCTSK | |
| SCHEMBL1486143 | 1.00 | APP (0.49) | APPPPARAPPARGCTSSCTSK | |
| Alanine SCHEMBL5917025 | 0.94 | APP (0.46) | APPPPARAPPARGCTSSCTSK | |
| SCHEMBL30096350 | 0.90 | ECE1 (0.46) | APPPPARAPPARGCTSSCTSK | |
| Valine SCHEMBL5917198 | 0.90 | ECE1 (0.46) | APPPPARAPPARGCTSSCTSK | |
| SCHEMBL7351243 | 0.88 | CYP1A2 (0.46) | APPPPARAPPARGCTSSCTSK | |
| SCHEMBL607556 | 0.88 | CYP1A2 (0.46) | APPPPARAPPARGCTSSCTSK | |
| SCHEMBL21638987 | 0.87 | CTSS (0.46) | PPARAPPARGCTSSCTSKPPARD | |
| SCHEMBL21638986 | 0.87 | CTSS (0.46) | PPARAPPARGCTSSCTSKPPARD | |
| SCHEMBL5072619 | 0.87 | CTSS (0.44) | APPPPARAPPARGCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-111116417-A | Cathepsin inhibitor and preparation method and application thereof | 辽宁医药职业学院 | 2020-05-08 | — | — | CN | claimed |
| US-12625431-B2 | EUV resist underlayer film-forming composition | NISSAN CHEMICAL CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4043447-B1 | HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVE, PREPARATION AND APPLICATION THEREOF | SHANGHAI QINGDONG BIOTECHNOLOGY CO LTD (CN) | 2026-01-21 | — | — | EP | disclosed |
| US-12496282-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| EP-4619037-A1 | SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-0574135-B1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORP (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5644028-A | Process for producing peptide derivatives and salts therefor | JAPAN ENERGY CORPORATION (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5508432-A | TREATING GASTROINTESTINAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5380872-A | Appetite suppresant, gall bladder disorders, CNS disorders | GLAXO INC. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5147865-A | Viricides | BAYER AKTIENGESELLSCHAFT (DE) | 1992-09-15 | — | — | US | disclosed |
| US-5145951-A | Protected ologopeptides; treating aids | BAYER AKTIENGESELLSCHAFT, A CORP. OF GERMANY (DE) | 1992-09-08 | — | — | US | disclosed |
| US-5047430-A | Glutamate Receptor Inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0437729-A2 | New peptides, procedure for their preparation and their use as a medicament, especially their use as medicament against retroviruses | BAYER AG (DE) | 1991-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | APP 526/4885PPARA 1878/4885PPARG 853/4885 |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CDR2 | APP 1846/4885PPARA 3972/4885PPARG 4028/4885 |
| US-12625431-B2 | EUV resist underlayer film-forming composition | EEF1A1, ARF1, EMG1 | APP 4214/4885PPARA 4500/4885PPARG 4375/4885 |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | APP 2652/4885PPARA 2981/4885PPARG 2633/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | APP 134/4885PPARA 1752/4885PPARG 2783/4885 |
| US-12496282-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | APP 1308/4885PPARA 1916/4885PPARG 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.